At Avidity, our goal is to discover, develop and commercialize novel AOC™ therapeutics that overcome current barriers to the delivery of oligonucleotides and unlock their potential to treat a wide range of serious diseases currently lacking adequate treatment options. 

We continue to broaden the reach of AOCs with our advancing and expanding pipeline as we transform to become a global commercial organization. In addition to our own internal research programs, we continue to explore the full potential of our AOC platform through collaborations and partnerships, including programs in immunology, cardiology and other select indications outside of muscle.

PRECISION CARDIOLOGY

In November 2023, Avidity announced a global licensing and research collaboration with Bristol Myers Squibb focused on the discovery, development and commercialization of multiple cardiovascular targets. This strategic collaboration broadens the reach of AOCs through the expansion of the existing relationship with Bristol Myers Squibb. In addition, we continue to advance our own internal research and development programs in rare cardiac indications.

IMMUNOLOGY

In April 2019, Avidity entered into a research collaboration and license agreement with Eli Lilly and Company for the discovery, development and commercialization of AOCs directed against certain targets in immunology and other select indications on a worldwide basis.